Recombinant vaccinia viruses protect against Clostridium perfringens α- toxin

Viral Immunology

Volumn 12, Issue 2, 1999, Pages 97-105

  Bennett, Alice M ^a   Lescott, Thelma ^a   Phillpotts, Robert J ^a   Mackett, Michael ^b   Titball, Richard W ^a  

^a DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; BACTERIAL VACCINE; CLOSTRIDIUM TOXIN; GLUTATHIONE TRANSFERASE; HYBRID PROTEIN; RECOMBINANT VACCINE; SERINE PROTEINASE INHIBITOR; THYMIDINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL INFECTION; CLOSTRIDIUM PERFRINGENS; CONTROLLED STUDY; FEMALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; VACCINATION; VACCINIA VIRUS; VIROGENESIS; VIRUS RECOMBINANT;

ANIMALIA; BACILLUS ANTHRACIS; BACTERIA (MICROORGANISMS); CLOSTRIDIUM; CLOSTRIDIUM PERFRINGENS; POSIBACTERIA; VACCINIA; VACCINIA VIRUS;

EID: 0032990763     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.1999.12.97     Document Type: Article

References (31)

1. Brochier, B., F. Costy, and P.-P. Pastoret. 1995. Elimination of fox rabies from Belgium using a recombinant vaccinia-rabies vaccine: an update. Vet. Microbiol. 46:269-279.
2. Buller, R.M.L., G.L. Smith, K. Cremer, A. Notkins, and B. Moss. 1985. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature. 317:813-815.
3. Cesbron-Delauw, P.R., G. Torpier, J.-Y. Cesbron, P. Leite, F. Darcy, A. Capron, B. Guy, G. Lenzen, and J.-P. Lecocq. 1989. A strategy for cloning potential protective antigens of Toxoplasma gondii, pp 301-304. In R.S. Lerner, H. Ginsberg, R.M. Chanock, and F. Brown, eds. Vaccines 89. Modern approaches to new vaccines including the prevention of AIDS. Cold Spring Harbor Laboratory Press, New York.
4. Cooney, E.L., A.C. Collier, P.D. Greenberg, R.W. Coombs, J. Zarling, D.E. Ardetti, M.C. Huffman, S.-L. Hu, and L. Corey. 1991. Safety and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet. 337:567-572.
5. Coupar, B.E.H., M.E. Andrew, and D.B. Boyle. 1988. A general method for the construction of recombinant vaccinia viruses expressing multiple foreign genes. Gene. 68:1-10.
6. Cygan, Z., and J. Buczek. 1993. Nonenterotoxigenic anaerobe C. perfringens A as a cause of calf diarrhoea. Medycyna Weter. 49:469-471.
7. Davison, AJ., and B. Moss. 1989. Structure of vaccinia virus early promoters. J. Mol. Biol. 210:749-769.
8. Erickson, A.L., and C.M. Walker. 1993. Class I major histocompatibility complex-restricted cytotoxic T cell responses to vaccinia virus in humans. J. Gen. Virol. 74:751-754.
9. Falkner, F.G., and B. Moss. 1988. Escherichia coli gpt gene provides dominant selection of vaccinia virus open reading frame expression vectors. J. Virol. 62:1849-1854.
10. Fenner, F., D.A. Henderson, I. Arita, Z. Jerek, and I.D. Ladnyi. 1988. Smallpox and its eradication. World Health Organisation, Geneva.
11. Iacono-Connors, L.C., C.S. Schmaljohn, and J.M. Dalrymple. 1990. Expression of the Bacillus anthracis protective antigen by baculovirus and vaccinia virus recombinants. Infect. Immun. 58:366-372.
12. Iacono-Connors, L.C., S.L. Welkos, B.E. Ivins, and J.M. Dalrymple. 1991. Protection against anthrax with recombinant virus-expressed protective antigen in experimental animals. Infect. Immun. 59:1961-1965.
13. Karayiannis, P., S. O'Rourke, M.J. McGarvey, S. Luther, J. Waters, R. Goldin, and H.C. Thomas. 1991. A recombinant vaccinia virus expressing hepatitis A virus structural polypeptides: characterization and demonstration of protective immunogenicity. J. Gen. Virol. 72:2167-2172.
14. Kettle, S., N.W. Blake, K.M. Law, and G.L. Smith. 1995. Vaccinia virus serpins B13R (SPI-2) and B22R (SPI-1) encode Mr 38.5 and 40 K, intracellular polypeptides that do not affect virus virulence in a murine intranasal model. Virology 206:136-147.
15. Kettle, S., A. Alcami, A. Khanna, R. Ehret, C. Jassoy, and G. Smith. 1997. Vaccinia virus serpin B13R (SPI-2) inhibits interleukin-1β-converting enzyme and protects virus-infected cells from TNF- and Fas-mediated apoptosis, but does not prevent IL-1β-induced fever. J. Gen. Virol. 78:677-685.
16. Langford, C.J., S.J. Edwards, G.L. Smith, G.F. Mitchell, B. Moss, D.J. Kemp, and R.F. Anders. 1986. Anchoring a secreted plasmodium antigen onto the surface of vaccinia virus infected cells increases its immunogenicity. Mol. Cell. Biol. 6:3191-3199.
17. MacPherson, W.G., A.A. Bowlby, C. Wallace, and C. English. 1922. Gas gangrene, pp 134-150. In Official History of the War, vol. 1. Medical Services Surgery of the War. His Majesty's Stationery Office, London.
18. McDonel, J.L. 1986. Toxins of Clostridium perfringens types A, B, C, D and E, pp 477-517. In F. Dorner, and J. Drews, eds. Pharmacology of bacterial toxins. Pergamon Press, Oxford.
19. Murrell, W.G., B.J. Stewart, C. O'Neill, S. Siarakas, and S. Kariks. 1993. Enterotoxigenic bacteria in the sudden infant death syndrome. J. Med. Microbiol. 39:114-127.
20. Nam, J.-H., L.S. Wyatt, S.-L. Chae, H.-W. Cho, Y.-K. Park, and B. Moss. 1999. Protection against lethal Japanese encephalitis virus infection of mice by immunization with the highly attenuated MVA strain of vaccinia virus expressing JEV prM and E genes. Vaccine. 17:261-268.
21. National Institute of Allergy and Infectious Diseases. 1992. The Jordan report. Accelerated development of vaccines. National Institutes of Health, Bethesda.
22. Perkus, M.E., A. Puccini, B.R. Lipinskas, and E. Paoletti. 1985. Recombinant vaccinia virus: immunization against multiple pathogens. Science. 229:728-731.
23. Smith, G.L., G.N. Godson, V. Nussenzweig, R.S. Nussenzweig, J. Barnwell, and B. Moss. 1984. Plasmodium knowlesi sporozoite antigen: expression by infectious recombinant vaccinia virus. Science. 224:397-399.
24. Smith, G.L., K.-C. Cheng, and B. Moss. 1986. Vaccinia virus: an expression vector for genes from parasites. Parasitology. 92(suppl):109-118.
25. Smith, G.L., S.T. Howard, and Y. Sang Chan. 1989. Vaccinia virus encodes a family of genes with homology to serine protease inhibitors. J. Gen. Virol. 70:2333-2343.
26. Tine, J.A., D.E. Lanar, D.M. Smith, B.T. Wellde, P. Schultheiss, L.A. Ware, E.B. Kauffman, R.A. Wirtz, C. De Taisne, G.S.N. Hui, S.P. Chang, P. Church, M.R. Hollingdale, D.C. Kaslow, S. Hoffman, K.P. Guito, W.R. Ballou, J.C. Sadoff, and E. Paoletti. 1996. NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Infect. Immun. 64:3833-3844.
27. Titball, R.W., A.M. Fearn, and E.D. Williamson. 1993. Biochemical and immunological properties of the C-terminal domain of the alpha-toxin of Clostridium perfringens. FEMS Microbiol. Lett. 110:45-50.
28. Williamson, E.D., and R.W. Titball. 1993. A genetically engineered vaccine against the alpha-toxin of Clostridium perfringens protects mice against experimental gas-gangrene. Vaccine. 11:1253-1258.
29. Willis, T.A. 1977. Anaerobic bacteriology, clinical and laboratory practice, 3rd ed. Butterworths, London.
30. Zhou, J., L. Crawford, L. McLean, X. Sun, M. Stanley, N. Almond, and G.L. Smith. 1990. Increased antibody responses to human papillomavirus type 16 L1 protein expressed by recombinant vaccinia virus lacking serine protease inhibitor genes. J. Gen. Virol. 71:2185-2190.
31. Zhu, X., N. Venkataprasad, J. Ivanyi, and H.M. Vordermeier. 1997.Vaccination with recombinant vaccinia viruses protects mice against Mycobacterium tuberculosis infection. Immunology. 92:6-9.